Loading
What changed between revision 1 and revision 2, compared over the article's markdown source with its frontmatter — so a change to status, evidence or reversibility shows up as the edit it is.
Older · revision 1
Import· initial corpus import, not an edit
Initial import of content/altos-labs.md — the filesystem corpus, unchanged. Not an edit.
11.7 kB
Revision 1
Revision 2
lines 7–13 → 7–136 unchanged lines not shown
categories: ["organizations", "longevity"]categories: ["organizations", "longevity"]tags: ["reprogramming", "rejuvenation", "biotech", "aging", "venture funding", "cell biology"]tags: ["reprogramming", "rejuvenation", "biotech", "aging", "venture funding", "cell biology"]summary: "A biotechnology company launched in 2022 with about three billion dollars in committed funding to develop cellular rejuvenation programming as a medicine."summary: "A biotechnology company launched in 2022 with about three billion dollars in committed funding to develop cellular rejuvenation programming as a medicine."updated: "2026-07-27"updated: "2026-10-29"issues: ["The $3 billion figure and the investor names rest on a single 2021 news report.", "The research programme section lists strands without citing the company's own publications."]issues: ["The $3 billion figure and the investor names rest on a single 2021 news report.", "The research programme section lists strands without citing the company's own publications."]------ lines 26–32 → 26–3212 unchanged lines not shown
}}`````` **Altos Labs** is a privately held biotechnology company, launched publicly in January 2022 with roughly three billion dollars in committed capital, that aims to turn [[epigenetic-reprogramming|cellular reprogramming]] into a treatment for age-related disease. It is among the largest single financial commitments made to rejuvenation biology, and as of 2026 it has published research but has not publicly named a clinical candidate. Its existence is the clearest evidence that reprogramming moved from an academic curiosity to an industrial programme; whether it can be made into a drug remains open.**Altos Labs** is a privately held biotechnology company, launched publicly in January 2022 with roughly three billion dollars in committed capital, that aims to turn [[epigenetic-reprogramming|cellular reprogramming]] into a treatment for age-related disease. It is among the largest single financial commitments made to rejuvenation biology, and as of 2026 it has published research but has not publicly named a clinical candidate. Its existence is the clearest evidence that reprogramming has moved from academic curiosity to industrial programme. Whether reprogramming can be made into a drug remains open. ```keyfacts```keyfacts[[lines 40–50 → 40–507 unchanged lines not shown
The company's stated goal is "cellular rejuvenation programming": restoring the function of aged or damaged cells by resetting their epigenetic state, without converting them into a different cell type and without producing tumours. Its scientific premise is that aging involves a substantial component of reversible epigenetic change rather than only irreversible damage, and that the [[yamanaka-factors]] provide a handle on it.The company's stated goal is "cellular rejuvenation programming": restoring the function of aged or damaged cells by resetting their epigenetic state, without converting them into a different cell type and without producing tumours. Its scientific premise is that aging involves a substantial component of reversible epigenetic change rather than only irreversible damage, and that the [[yamanaka-factors]] provide a handle on it. Altos was assembled unusually. Rather than licensing a technology and building a pipeline, it recruited senior academic laboratories more or less intact, paid salaries reported to be several times academic norms, and gave principal investigators freedom to publish. The structure resembles a privately funded research institute more than a conventional startup, and the company has said this is deliberate: the underlying biology is not considered ready for a development programme.Altos was assembled unusually. Rather than licensing a technology and building a pipeline, it recruited senior academic laboratories more or less intact, paid salaries reported to be several times academic norms, and gave principal investigators freedom to publish. The structure resembles a privately funded research institute more than a conventional startup. The company has said this is deliberate, because it does not consider the underlying biology ready for a development programme. ## History## History The company was incorporated quietly in 2021 and reported before its public launch by MIT Technology Review, which described a recruitment campaign among leading aging and reprogramming researchers and named Jeff Bezos and Yuri Milner among the backers.[^regalado2021] It launched formally in January 2022 with Hal Barron, previously chief scientific officer at GSK and before that at Genentech, as chief executive; Rick Klausner, a former director of the US National Cancer Institute, as chief scientist; and Hans Bishop, a founder of Juno Therapeutics, as president.The company was incorporated quietly in 2021 and reported before its public launch by MIT Technology Review, which described a recruitment campaign among leading aging and reprogramming researchers and named Jeff Bezos and Yuri Milner among the backers.[^regalado2021] It launched formally in January 2022. Hal Barron, previously chief scientific officer at GSK and before that at Genentech, became chief executive; Rick Klausner, a former director of the US National Cancer Institute, chief scientist; and Hans Bishop, a founder of Juno Therapeutics, president. Juan Carlos Izpisua Belmonte, whose Salk Institute laboratory produced the founding demonstration of [[partial-reprogramming]] in living mice, moved to Altos with much of his group. Other recruits included Manuel Serrano from Barcelona, Wolf Reik from the Babraham Institute in Cambridge, and [[steve-horvath|Steve Horvath]], whose work established the [[epigenetic-clock]] as a measurement tool. [[shinya-yamanaka]] agreed to serve as a senior scientific adviser while remaining at Kyoto University.Juan Carlos Izpisua Belmonte, whose Salk Institute laboratory produced the founding demonstration of [[partial-reprogramming]] in living mice, moved to Altos with much of his group. Other recruits included Manuel Serrano from Barcelona, Wolf Reik from the Babraham Institute in Cambridge, and [[steve-horvath|Steve Horvath]], whose work established the [[epigenetic-clock]] as a measurement tool. [[shinya-yamanaka]] agreed to serve as a senior scientific adviser while remaining at Kyoto University. lines 54–70 → 54–703 unchanged lines not shown
{ "year": "2016", "title": "Partial reprogramming in vivo", "text": "Izpisua Belmonte's Salk group reports that cyclic, short-duration expression of the factors extends lifespan in a progeria mouse model and improves tissue repair after injury in normal mice." }, { "year": "2016", "title": "Partial reprogramming in vivo", "text": "Izpisua Belmonte's Salk group reports that cyclic, short-duration expression of the factors extends lifespan in a progeria mouse model and improves tissue repair after injury in normal mice." }, { "year": "2021", "title": "Quiet assembly", "text": "Reports emerge of a well-funded new company recruiting senior reprogramming and aging researchers under confidentiality." }, { "year": "2021", "title": "Quiet assembly", "text": "Reports emerge of a well-funded new company recruiting senior reprogramming and aging researchers under confidentiality." }, { "year": "2022", "title": "Public launch", "text": "Altos Labs announces itself with about $3 billion committed, three research institutes, and a leadership drawn from large-pharma R&D." }, { "year": "2022", "title": "Public launch", "text": "Altos Labs announces itself with about $3 billion committed, three research institutes, and a leadership drawn from large-pharma R&D." }, { "year": "2022–2026", "title": "Publication without clinic", "text": "The company's laboratories publish on reprogramming mechanism, cell identity and epigenetic ageing; no clinical programme is announced." } { "year": "2022-2026", "title": "Publication without clinic", "text": "The company's laboratories publish on reprogramming mechanism, cell identity and epigenetic ageing; no clinical programme is announced." }]]`````` ## Research programme## Research programme The technical problem Altos works on is narrow and well defined. The four factors identified by Takahashi and Yamanaka return an adult cell to pluripotency when expressed continuously,[^takahashi2006] which in a living animal erases cell identity and causes teratomas. Transient or cyclic expression appears instead to restore youthful gene-expression patterns while leaving identity intact, a result first shown in vivo by Ocampo and colleagues in 2016.[^ocampo2016] A separate line of work from [[david-sinclair]]'s laboratory reported that expressing three of the factors in retinal ganglion cells restored vision in mice after optic-nerve crush and in aged animals, and argued that the recovered information is epigenetic rather than genetic.[^lu2020] The company's work concerns what determines where on that spectrum a cell lands, how to deliver the intervention to a chosen tissue, and how to measure the result in something more meaningful than a clock reading.The technical problem Altos works on is narrow and well defined. Expressed continuously, the four factors identified by Takahashi and Yamanaka return an adult cell to pluripotency,[^takahashi2006] which in a living animal erases cell identity and causes teratomas. Transient or cyclic expression instead appears to restore youthful gene-expression patterns while leaving identity intact, a result first shown in vivo by Ocampo and colleagues in 2016.[^ocampo2016] A separate line of work from [[david-sinclair]]'s laboratory reported that expressing three of the factors in retinal ganglion cells restored vision in mice after optic-nerve crush and in aged animals, and argued that the recovered information is epigenetic rather than genetic.[^lu2020] The company studies what determines where on that spectrum a cell lands, how to deliver the intervention to a chosen tissue, and how to measure the result by something more meaningful than a clock reading. Several strands are visible in its published output and public statements:Its published output and public statements show several strands of work: - **Mechanism of rejuvenation.** Distinguishing the epigenetic changes that carry functional age from those that merely correlate with it, which is the same problem that makes [[biological-age]] measurement contested.- **Mechanism of rejuvenation.** Distinguishing the epigenetic changes that carry functional age from those that merely correlate with it, the same problem that makes [[biological-age]] measurement contested.- **Factor and dose engineering.** Alternatives to the canonical four factors, including OSK without Myc and non-Yamanaka transcription-factor sets, and control of expression duration.- **Factor and dose engineering.** Alternatives to the canonical four factors, including OSK without Myc and non-Yamanaka transcription-factor sets, and control of expression duration.- **Delivery.** Reaching a specific tissue in an adult animal, the bottleneck that also constrains [[somatic-gene-therapy]] generally, using [[aav-vectors]] and [[lipid-nanoparticles]] among other approaches.- **Delivery.** Reaching a specific tissue in an adult animal, the bottleneck that also constrains [[somatic-gene-therapy]] generally, using [[aav-vectors]] and [[lipid-nanoparticles]] among other approaches.- **Readouts.** Functional endpoints such as regenerative capacity after injury, rather than [[aging-biomarkers|biomarker]] shifts alone.- **Readouts.** Functional endpoints such as regenerative capacity after injury, rather than [[aging-biomarkers|biomarker]] shifts alone.lines 76–88 → 76–885 unchanged lines not shown
The three-billion-dollar figure refers to capital committed at launch rather than money spent, and Altos has not published financial statements. Reported backers include Bezos and Milner; the company has not confirmed the full investor list. It operates institutes in the San Francisco Bay Area, San Diego, and Cambridge in the United Kingdom, with a stated intention to build further sites.The three-billion-dollar figure refers to capital committed at launch rather than money spent, and Altos has not published financial statements. Reported backers include Bezos and Milner; the company has not confirmed the full investor list. It operates institutes in the San Francisco Bay Area, San Diego, and Cambridge in the United Kingdom, with a stated intention to build further sites. The scale matters for a structural reason. Rejuvenation research has historically been funded either by government grants, which are allocated to hypothesis-driven projects on short cycles, or by philanthropic bodies such as the [[sens-research-foundation]] and [[methuselah-foundation]], which had budgets several orders of magnitude smaller. Altos can run a decade of preclinical work without a product, which is a genuinely different experiment in how the field might progress. It is also a concentration of talent that removes senior investigators from university training pipelines, a cost the [[buck-institute]] and other academic centres have noted.The scale matters because of how the field has been funded. Rejuvenation research has historically been funded either by government grants, which are allocated to hypothesis-driven projects on short cycles, or by philanthropic bodies such as the [[sens-research-foundation]] and [[methuselah-foundation]], which had budgets several orders of magnitude smaller. Altos can run a decade of preclinical work without a product, a genuinely different experiment in how the field might progress. It also concentrates talent, removing senior investigators from university training pipelines, a cost the [[buck-institute]] and other academic centres have noted. ## Reception## Reception Scientific reception has been guarded rather than hostile. The underlying result is real and reproducible, and few biogerontologists dispute that partial reprogramming does something to aged cells. The disputes are about interpretation and translation.Scientific reception has been guarded rather than hostile. The underlying result is real and reproducible, and few biogerontologists dispute that partial reprogramming does something to aged cells. The disputes are about interpretation and translation. The interpretive question is what "rejuvenation" means when its main evidence is a shift in DNA methylation patterns. A change in a methylation clock reading is a change in a correlate; it is not by itself evidence that an organism is functionally younger, and the field has no surrogate endpoint that a regulator would accept. This is the same gap that constrains the whole [[geroscience-hypothesis]] programme.The interpretive question is what "rejuvenation" means when its main evidence is a shift in DNA methylation patterns. A change in a methylation clock reading is a change in a correlate. By itself it is not evidence that an organism is functionally younger, and the field has no surrogate endpoint that a regulator would accept. The same gap constrains the whole [[geroscience-hypothesis]] programme. The translational question is safety. The factors that rejuvenate are the factors that cause cancer; Myc is an oncogene, and dedifferentiated cells are the raw material of tumours. A therapy given to healthy older people for prevention faces a far higher safety bar than one given to patients with a fatal disease, and no dosing regime has been shown to be safe in a large mammal over years.The translational question is safety. The factors that rejuvenate are the factors that cause cancer; Myc is an oncogene, and dedifferentiated cells are the raw material of tumours. A therapy given to healthy older people for prevention faces a far higher safety bar than one given to patients with a fatal disease, and no dosing regime has been shown to be safe in a large mammal over years. lines 90–98 → 90–981 unchanged line not shown
## Outlook## Outlook The informative signals over the next several years will be specific. Does Altos publish a functional rejuvenation result in a large, long-lived mammal rather than a mouse? Does it name a first indication, and is that indication an acute tissue injury — where a short course of reprogramming has a plausible risk-benefit case — rather than aging itself? Does it disclose a delivery method that reaches a solid organ at a therapeutic dose without dosing the whole body?The informative signals over the next several years will be specific. One is whether Altos publishes a functional rejuvenation result in a large, long-lived mammal rather than a mouse. Another is whether it names a first indication, and whether that indication is an acute tissue injury, where a short course of reprogramming has a plausible risk-benefit case, rather than aging itself. A third is whether it discloses a delivery method that reaches a solid organ at a therapeutic dose without dosing the whole body. If reprogramming turns out to be a treatment for particular injuries rather than a general intervention against aging, that would still be a substantial result and a poor return on three billion dollars aimed at the latter. The company's founding wager is that the two are the same problem at different doses, and nothing yet published settles it.If reprogramming turns out to treat particular injuries rather than to act as a general intervention against aging, that would still be a substantial result, though a poor return on three billion dollars aimed at the latter. The company's founding wager is that the two are the same problem at different doses, and nothing yet published settles it. ## See also## See also removed, struck through added, underlinedLine numbers count the serialised markdown of each revision, frontmatter included.
102 lines are the same in both revisions, and 50 of them are not shown. Neither revision here is necessarily the current article — read Altos Labs for the text this wiki stands behind today.